Autolus Therapeutics Plc (AUTL) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Autolus Therapeutics Plc  (NASDAQ: AUTL)
 

Autolus Therapeutics Plc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Due to inventory build up in the second quarter 2026, Autolus Therapeutics Plc's inventory turnover ratio sequentially decreased to 8.08 in the second quarter 2026, unsurprisingly, as the Autolus Therapeutics Plc markets continue to deteriorate, and AUTL's faces growing challenges to bring down its inventories. Autolus Therapeutics Plc's average inventory processing period in the Jun 30 2026 quarter, has increased to 45 days, from 15 days, in the Mar 31 2026 quarter.

Within Healthcare sector 40 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 150 in the first quarter 2026, to 174.

AUTL Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Autolus Therapeutics Plc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

AUTL Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth 1729.83 % 433.59 % 3753.57 % - -
Y / Y Cost of Sales Growth -16.27 % 36.86 % 122.45 % - -
Inventory Turnover Ratio (TTM) 8.08 23.69 34.23 54.9 63.63
AUTL's Total Ranking # 174 # 150 # 80 # #
Average inventory processing period 45 15 11 7 6
Seq. Inventory Growth 343.09 % 39.85 % 105.6 % 43.62 % 29.21 %
Seq. Cost of Sales Growth -16.69 % -3.01 % -11.57 % 17.17 % 36.18 %




Inventory Turnover Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 2
Healthcare Sector # 41
Overall Market # 174

Inventory Turnover Ratio Statistics
High Average Low
54.9 30.23 8.08
(Sep 30 2025)   (Jun 30 2026)



AUTL Company Profile >> Back to AUTL Efficiency Comparisons >> Compare AUTL Inventory Turnover Ratio to its Competitors

Financial Statements
Autolus Therapeutics Plc's Inventories $ 33 Millions Visit AUTL's Balance sheet
Autolus Therapeutics Plc's Cost of Revenues TTM $ 99 Millions Visit AUTL's Income Statement
What are AUTL's Sales? Visit AUTL's Sales by Segment

Other Inventory Turnover Ratios
Autolus Therapeutics Plc's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Biotechnology & Pharmaceuticals Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
AUTL's Inventory Turnover Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for AUTL's Competitors
Inventory Turnover Ratio for AUTL's Suppliers
Inventory Turnover Ratio for AUTL's Customers

You may also want to know
AUTL's Sales Growth Rates AUTL's Pe Price to earnings ratio AUTL's Receivables Turnover Ratio AUTL's Stock Quote
AUTL's Net Income Growth Rates AUTL's Ps Price to Sales ratio AUTL's Sales per Employee AUTL's Asset Turnover Ratio
AUTL's Net Margin AUTL's Pb Price to Book ratio AUTL's Financial Strength Ratios AUTL's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Autolus Therapeutics Plc  8.08 $ 99.009  Millions$ 12  Millions
The Oncology Institute Inc   8.03 $ 160.655  Millions$ 20  Millions
Nutriband Inc   7.92 $ 1.082  Millions$ 0  Millions
Inogen Inc   7.51 $ 196.617  Millions$ 26  Millions
Moderna Inc   7.50 $ 1,707.000  Millions$ 228  Millions
Cardiff Lexington Corporation  7.49 $ 4.042  Millions$ 1  Millions
Adaptive Biotechnologies Corporation  7.26 $ 75.254  Millions$ 10  Millions
Adm Tronics Unlimited Inc   6.05 $ 1.970  Millions$ 0  Millions
Sharps Technology Inc   5.68 $ 2.869  Millions$ 1  Millions
Transmedics Group Inc   5.59 $ 276.120  Millions$ 49  Millions
Opko Health Inc   5.42 $ 348.206  Millions$ 64  Millions
Charles River Laboratories International inc   5.39 $ 1,761.363  Millions$ 327  Millions
Tactile Systems Technology Inc   5.12 $ 81.349  Millions$ 16  Millions
Integer Holdings Corporation  5.03 $ 1,369.168  Millions$ 272  Millions
Harrow Inc   4.93 $ 73.636  Millions$ 15  Millions
Ufp Technologies Inc   4.93 $ 452.046  Millions$ 92  Millions
Veracyte Inc   4.84 $ 102.741  Millions$ 21  Millions
West Pharmaceutical Services Inc   4.72 $ 2,103.100  Millions$ 445  Millions
Henry Schein Inc   4.68 $ 9,342.000  Millions$ 1,997  Millions
Guardant Health Inc   4.53 $ 413.947  Millions$ 91  Millions
Idexx Laboratories Inc  4.44 $ 1,714.440  Millions$ 386  Millions
Adc Therapeutics Sa  4.17 $ 5.806  Millions$ 1  Millions
Scilex Holding Company  4.08 $ 14.867  Millions$ 4  Millions
Medinotec Inc   4.08 $ 4.736  Millions$ 1  Millions
3m Company  4.07 $ 15,258.000  Millions$ 3,754  Millions
Electromed Inc   4.02 $ 14.133  Millions$ 4  Millions
Novocure Limited  4.02 $ 166.921  Millions$ 41  Millions
Elite Pharmaceuticals Inc   3.95 $ 78.824  Millions$ 20  Millions
Lftd Partners Inc   3.89 $ 29.233  Millions$ 8  Millions
Pmgc Holdings Inc   3.87 $ 1.364  Millions$ 0  Millions

Date modified: 2026-09-04T10:02:10+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.